+74.3%
USO vs MRNA
+554.4%
-480.1%
-84.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | +5.4% | -7.6% | -2.1% |
| 7D | +9.1% | -1.1% | +10.2% | +9.1% |
| 30D | +21.7% | +126.1% | -104.4% | +24.7% |
| 3M | +20.2% | +190.0% | -169.8% | +24.3% |
| 6M | +43.4% | +157.2% | -113.9% | +48.1% |
| YTD | +124.0% | +388.2% | -264.2% | +133.5% |
| 1Y | +112.2% | +467.0% | -354.8% | +121.9% |
| 3Y | +97.7% | +36.1% | +61.6% | +102.8% |
| 5Y | +217.4% | -68.0% | +285.4% | +224.2% |
| All | +74.3% | +554.4% | -480.1% | +78.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling